Do Valsartan and Losartan Have the Same Effects in the Treatment of Coronary Artery Disease?-Reference-Cited by-同舟云学术

Do Valsartan and Losartan Have the Same Effects in the Treatment of Coronary Artery Disease?

Published:2007 Issue:1 Volume:71 Page:32-38
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Iwata Atsushi¹,Miura Shin-ichiro¹,Imaizumi Satoshi¹,Kiya Yoshihiro¹,Nishikawa Hiroaki¹,Zhang Bo¹,Shimomura Hideki²,Kumagai Koichiro¹,Matsuo Kunihiro¹,Shirai Kazuyuki¹,Saku Keijiro¹

Affiliation:

1. Department of Cardiology, Fukuoka University School of Medicine

2. Division of Cardiology, Fukuoka Tokusyukai Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/71/1/71_1_32/_pdf

Reference31 articles.

1. 1. De Gasparo M, Catt K, Inagami T, Wright JW, Unger T. International Union of Pharmacology. XXIII: The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.

2. 2. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 2006; 70: 995-1000.

3. 3. Inamoto S, Hayashi T, Tazawa N, Mori T, Yamashita C, Nakano D, et al. Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. Circ J 2006; 70: 787-792.

4. 4. Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21: 76-86.

5. 5. Matsuda H, Hayashi K, Homma K, Yoshioka K, Kanda T, Takamatsu I, et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res 2003; 26: 875-880.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulation and immunopharmacology in heart failure;Nature Reviews Cardiology;2023-09-14

2. The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated common marmosets;Journal of Pharmacological Sciences;2023-07

3. The short‐term effects of angiotensin II receptor blockers on albuminuria and renal function in Korean patients;Basic & Clinical Pharmacology & Toxicology;2019-12-11

4. Inhibition of Atherosclerosis by Angiotensin II Type 1 Receptor Antagonists;American Journal of Cardiovascular Drugs;2013-04-23

5. Comparison of the Efficacies of Irbesartan and Olmesartan after Successful Coronary Stent Implantation;Internal Medicine;2013